EyePoint Pharmaceuticals Inc (EYPT)

[jupp]

The deal with Alimera in terms of outside The United States includes 20% net profits on a country by country basis and pSivida has full audit rights. If Alimera decides to partner out the European commercialization then PSDV is entitled to 33 percent of any upfront and or milestone payments and 20 percent of whatever Alimera gets in royalties.

www.biomedreports.com/2012062798494/psivida-small-cap-ophthalmology-based-biotech-positioned-for-long-term-growth.html